Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro

Nathan Robbins, Mark Gilbert, Mohit Kumar, James W McNamara, Patrick Daly, Sheryl E Koch, Ginger Conway, Mohamed Effat, Jessica G Woo, Sakthivel Sadayappan, Jack Rubinstein, Nathan Robbins, Mark Gilbert, Mohit Kumar, James W McNamara, Patrick Daly, Sheryl E Koch, Ginger Conway, Mohamed Effat, Jessica G Woo, Sakthivel Sadayappan, Jack Rubinstein

Abstract

Background: Transient receptor potential vanilloid 2 is a calcium channel activated by probenecid. Probenecid is a Food and Drug Administration-approved uricosuric drug that has recently been shown to induce positive lusitropic and inotropic effects in animal models through cardiomyocyte transient receptor potential vanilloid 2 activation. The aim of this study was to test the hypothesis that oral probenecid can improve cardiac function and symptomatology in patients with heart failure with reduced ejection fraction and to further elucidate its calcium-dependent effects on myocyte contractility.

Methods and results: The clinical trial recruited stable outpatients with heart failure with reduced ejection fraction randomized in a single-center, double-blind, crossover design. Clinical data were collected including a dyspnea assessment, physical examination, ECG, echocardiogram to assess systolic and diastolic function, a 6-minute walk test, and laboratory studies. In vitro force generation studies were performed on cardiomyocytes isolated from murine tissue exposed to probenecid or control treatments. The clinical trial recruited 20 subjects (mean age 57 years, mean baseline fractional shortening of 13.6±1.0%). Probenecid therapy increased fractional shortening by 2.1±1.0% compared with placebo -1.7±1.0% (P=0.007). Additionally, probenecid improved diastolic function compared with placebo by decreasing the E/E' by -2.95±1.21 versus 1.32±1.21 in comparison to placebo (P=0.03). In vitro probenecid increased myofilament force generation (92.36 versus 80.82 mN/mm2, P<0.05) and calcium sensitivity (pCa 5.67 versus 5.60, P<0.01) compared with control.

Conclusions: Probenecid improves cardiac function with minimal effects on symptomatology and no significant adverse effects after 1 week in patients with heart failure with reduced ejection fraction and increases force development and calcium sensitivity at the cardiomyocyte level.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01814319.

Keywords: Probenecid; TRPV2; echocardiography.

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Figures

Figure 1
Figure 1
Effect of probenecid on systolic function. A, Change in fractional shortening (FS) after probenecid and placebo. B, Relationship between change in FS and baseline FS after probenecid. C, Relationship between change in FS and baseline FS after placebo. (*P<0.01).
Figure 2
Figure 2
Effect of probenecid on diastolic function. A, Change in E/E′ ratio after probenecid and placebo. B, Relationship between change in E/E′ and baseline E/E′ after probenecid. C, Relationship between change in E/E′ and baseline E/E′ after placebo. (*P=0.03).
Figure 3
Figure 3
Effect of probenecid on contractility of cardiomyocytes. A, Representative figure of attached cardiomyocytes. B and D, Force‐pCa curves generated from myocytes of saline, isoproterenol (Iso), and probenecid. C and E, Calcium sensitivity of cardiomyocytes from hearts treated with saline, Iso, and probenecid. F, Hill coefficient as an index of cooperative activation of the cardiomyocytes from hearts treated with saline, Iso, and probenecid. (*P<0.05). pCa indicates calcium sensitivity.

References

    1. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958–3968.
    1. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J. In‐hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64.
    1. Goldhaber JI, Hamilton MA. Role of inotropic agents in the treatment of heart failure. Circulation. 2010;121:1655–1660.
    1. Nagy L, Pollesello P, Papp Z. Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. J Cardiovasc Pharmacol. 2014;64:199–208.
    1. Endoh M. Ca 2+ in cardiac E‐C coupling. Circ J. 2008;72:1915–1925. Available at: . Accessed June 28, 2017.
    1. Singh K, Xiao L, Remondino A, Sawyer DB, Colucci WS. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol. 2001;189:257–265.
    1. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence‐based approach. Am Heart J. 2001;142:393–401.
    1. Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali J, Horton DP, Aronson D. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol. 2001;88:35–39.
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–e327.
    1. Clapham DE. TRP channels as cellular sensors. Nature. 2003;426:517–524.
    1. Muraki K, Iwata Y, Katanosaka Y, Ito T, Ohya S, Shigekawa M, Imaizumi Y. TRPV2 is a component of osmotically sensitive cation channels in murine aortic myocytes. Circ Res. 2003;93:829–838.
    1. Makarewich CA, Zhang H, Davis J, Correll RN, Trappanese DM, Hoffman NE, Troupes CD, Berretta RM, Kubo H, Madesh M, Chen X, Gao E, Molkentin JD, Houser SR. Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ Res. 2014;115:567–580.
    1. Yin J, Kuebler WM. Mechanotransduction by TRP channels: general concepts and specific role in the vasculature. Cell Biochem Biophys. 2010;56:1–18.
    1. Robbins N, Koch SE, Tranter M, Rubinstein J. The history and future of probenecid. Cardiovasc Toxicol. 2012;12:1–9.
    1. Iwata Y, Katanosaka Y, Arai Y, Komamura K, Miyatake K, Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2+‐permeable growth factor‐regulated channel. J Cell Biol. 2003;161:957–967.
    1. Koch SE, Mann A, Jones S, Robbins N, Alkhattabi A, Worley MC, Gao X, Lasko‐Roiniotis VM, Karani R, Fulford L, Jiang M, Nieman M, Lorenz JN, Rubinstein J. Transient receptor potential vanilloid 2 function regulates cardiac hypertrophy via stretch‐induced activation. J Hypertens. 2017;35:602–611.
    1. Koch SE, Gao X, Haar L, Jiang M, Lasko VM, Robbins N, Cai W, Brokamp C, Varma P, Tranter M, Liu Y, Ren X, Lorenz JN, Wang H‐S, Jones WK, Rubinstein J. Probenecid: novel use as a non‐injurious positive inotrope acting via cardiac TRPV2 stimulation. J Mol Cell Cardiol. 2012;53:134–144.
    1. Koch SE, Tranter M, Robbins N, Luther K, Singh U, Jiang M, Ren X, Tee T, Smith L, Varma P, Jones WK, Rubinstein J. Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model. J Cardiovasc Pharmacol Ther. 2013;18:280–289.
    1. Rubinstein J, Lasko VM, Koch SE, Singh VP, Carreira V, Robbins N, Patel AR, Jiang M, Bidwell P, Kranias EG, Jones WK, Lorenz JN. Novel role of transient receptor potential vanilloid 2 in the regulation of cardiac performance. Am J Physiol Heart Circ Physiol. 2014;306:H574–H584.
    1. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981;6:135–151.
    1. Craft JC, Feldman WE, Nelson JD. Clinicopharmacological evaluation of amoxicillin and probenecid against bacterial meningitis. Antimicrob Agents Chemother. 1979;16:346–352.
    1. Laskin OL, de Miranda P, King DH, Page DA, Longstreth JA, Rocco L, Lietman PS. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother. 1982;21:804–807.
    1. Boger WP. Probenecid (benemid). AMA Arch Intern Med. 1955;95:83.
    1. Bang S, Kim KY, Yoo S, Lee S‐H, Hwang SW. Transient receptor potential V2 expressed in sensory neurons is activated by probenecid. Neurosci Lett. 2007;425:120–125.
    1. Pang PS, Collins SP, Sauser K, Andrei A‐C, Storrow AB, Hollander JE, Tavares M, Spinar J, Macarie C, Raev D, Nowak R, Gheorghiade M, Mebazaa A. Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between likert and visual analog scales. Acad Emerg Med. 2014;21:659–666.
    1. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MSJ, Stewart WJ; Chamber Quantification Writing Group, American Society of Echocardiography's Guidelines and Standards Committee, European Association of Echocardiography. . Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463.
    1. Institutional Animal Care and Use Committee . Guide for the Care and Use of Laboratory Animals: Eighth Edition Guide for the Care and Use of Laboratory Animals. THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001. 2011:118.
    1. Kumar M, Govindan S, Zhang M, Khairallah RJ, Martin JL, Sadayappan S, de Tombe PP. Cardiac myosin‐binding protein C and troponin‐I phosphorylation independently modulate myofilament length‐dependent activation. J Biol Chem. 2015;290:29241–29249.
    1. Butler J, Fonarow GC, Gheorghiade M. Strategies and opportunities for drug development in heart failure. JAMA. 2013;309:1593–1594.
    1. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.
    1. Lorin C, Vögeli I, Niggli E. Dystrophic cardiomyopathy: role of TRPV2 channels in stretch‐induced cell damage. Cardiovasc Res. 2015;106:153–162.
    1. Shibasaki K, Murayama N, Ono K, Ishizaki Y, Tominaga M. TRPV2 enhances axon outgrowth through its activation by membrane stretch in developing sensory and motor neurons. J Neurosci. 2010;30:4601–4612.
    1. Katanosaka Y, Iwasaki K, Ujihara Y, Takatsu S, Nishitsuji K, Kanagawa M, Sudo A, Toda T, Katanosaka K, Mohri S, Naruse K. TRPV2 is critical for the maintenance of cardiac structure and function in mice. Nat Commun. 2014;5:3932.
    1. Selen A, Amidon GL, Welling PG. Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci. 1982;71:1238–1242.
    1. Sowunmi A, Fehintola FA, Adedeji AA, Gbotosho GO, Falade CO, Tambo E, Fateye BA, Happi TC, Oduola AMJ. Open randomized study of pyrimethamine‐sulphadoxine vs. pyrimethamine‐sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Trop Med Int Health. 2004;9:606–614.
    1. Shaywitz BA, Cohen DJ, Bowers MB. CSF monoamine metabolites in children with minimal brain dysfunction: evidence for alteration of brain dopamine. J Pediatr. 1977;90:67–71.
    1. Di Virgilio F, Steinberg T, Silverstein S. Inhibition of Fura‐2 sequestration and secretion with organic anion transport blockers. Cell Calcium. 1990;11:57–62.
    1. Bronsky D, Dubin A, Kushner DS. Diuretic action of benemid. Am J Med. 1955;18:259–266.
    1. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta‐adrenergic pathway. Circulation. 1998;98:1329–1334.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi